Financing
Debt Repayments
Labcorp Holdings Debt Repayments decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $1.00B to $0.00. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryLeverage
SignalLower is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
A decrease may indicate a focus on capital preservation or refinancing, while a significant increase signals active debt reduction or maturity fulfillment.
Detailed definition
Represents the total cash outflows used to reduce the principal balance of short-term and long-term debt obligations. Th...
Peer comparison
Standard across all capital-intensive industries; peers with high leverage typically show higher repayment activity.
Metric ID:
debt_repaymentHistorical Data
15 periods
| Q2 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $625.00M | $0.00 | $0.00 | $0.00 | $0.00 | $827.90M | $593.00M | -$1.42B | $300.00M | $0.00 | $0.00 | $600.00M | $400.00M | $1.00B | $0.00 |
| QoQ Change | — | -100.0% | — | — | — | — | -28.4% | -339.6% | +121.1% | -100.0% | — | — | -33.3% | +150.0% | -100.0% |
| YoY Change | — | — | -100.0% | — | — | — | — | — | — | -100.0% | -100.0% | +142.2% | +33.3% | — | -100.0% |
Range-$1.42B – $1.00B
CAGR-100.0%
Avg YoY Growth-37.4%
Median YoY Growth-100.0%
Debt Repayments at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's debt repayments?
- Labcorp Holdings (LH) reported debt repayments of $0.00 in Q1 2026.
- How has Labcorp Holdings's debt repayments changed year-over-year?
- Labcorp Holdings's debt repayments decreased by 100.0% year-over-year, from $1.00B to $0.00.
- What does debt repayments mean?
- The total amount of cash used to pay down debt principal.